| Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced … SE Al-Batran, N Homann, C Pauligk, TO Goetze, J Meiler, S Kasper, ... The Lancet 393 (10184), 1948-1957, 2019 | 1922 | 2019 |
| One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial H Joensuu, M Eriksson, KS Hall, JT Hartmann, D Pink, J Schütte, ... Jama 307 (12), 1265-1272, 2012 | 1154 | 2012 |
| Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate E Wardelmann, S Merkelbach-Bruse, K Pauls, N Thomas, HU Schildhaus, ... Clinical Cancer Research 12 (6), 1743-1749, 2006 | 460 | 2006 |
| Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour P Hohenberger, U Ronellenfitsch, O Oladeji, D Pink, P Ströbel, ... Journal of British Surgery 97 (12), 1854-1859, 2010 | 269 | 2010 |
| Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial H Joensuu, M Eriksson, K Sundby Hall, A Reichardt, JT Hartmann, D Pink, ... Journal of Clinical Oncology 34 (3), 244-250, 2016 | 233 | 2016 |
| Angiotensin II directly increases transforming growth factor β1 and osteopontin and indirectly affects collagen mRNA expression in the human heart C Kupfahl, D Pink, K Friedrich, HR Zurbrügg, M Neuss, C Warnecke, ... Cardiovascular research 46 (3), 463-475, 2000 | 232 | 2000 |
| Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature D Pink, T Lindner, A Mrozek, A Kretzschmar, PC Thuss-Patience, ... Gynecologic oncology 101 (3), 464-469, 2006 | 217 | 2006 |
| Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical … H Joensuu, E Wardelmann, H Sihto, M Eriksson, KS Hall, A Reichardt, ... JAMA oncology 3 (5), 602-609, 2017 | 190 | 2017 |
| Diffusion‐weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft‐tissue sarcomas O Dudeck, M Zeile, D Pink, M Pech, PU Tunn, P Reichardt, WD Ludwig, ... Journal of Magnetic Resonance Imaging: An Official Journal of the …, 2008 | 171 | 2008 |
| Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study PC Thuss-Patience, A Kretzschmar, M Repp, D Kingreen, D Hennesser, ... Journal of Clinical Oncology 23 (3), 494-501, 2005 | 164 | 2005 |
| Survival and prognostic factors in chondrosarcoma: results in 115 patients with long-term follow-up D Andreou, S Ruppin, S Fehlberg, D Pink, M Werner, PU Tunn Acta orthopaedica 82 (6), 749-755, 2011 | 160 | 2011 |
| Chemotherapy in alveolar soft part sarcomas: what do we know? P Reichardt, T Lindner, D Pink, PC Thuss-Patience, A Kretzschmar, ... European Journal of Cancer 39 (11), 1511-1516, 2003 | 142 | 2003 |
| A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors GD Demetri, PG Casali, JY Blay, M von Mehren, JA Morgan, R Bertulli, ... Clinical Cancer Research 15 (18), 5910-5916, 2009 | 127 | 2009 |
| Substrate rigidity controls activation and durotaxis in pancreatic stellate cells D Lachowski, E Cortes, D Pink, A Chronopoulos, SA Karim, J P. Morton, ... Scientific reports 7 (1), 2506, 2017 | 125 | 2017 |
| Sorafenib as third-or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective … M Montemurro, H Gelderblom, U Bitz, J Schütte, JY Blay, H Joensuu, ... European Journal of Cancer 49 (5), 1027-1031, 2013 | 101 | 2013 |
| Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA … RD Hofheinz, GM Haag, TJ Ettrich, K Borchert, A Kretzschmar, ... Journal of Clinical Oncology 38 (15_suppl), 4502-4502, 2020 | 88 | 2020 |
| Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib H Joensuu, M Eriksson, KS Hall, JT Hartmann, D Pink, J Schütte, ... Cancer 120 (15), 2325-2333, 2014 | 86 | 2014 |
| Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases D Pink, D Schoeler, T Lindner, PC Thuss-Patience, A Kretzschmar, ... Journal of Clinical Oncology 23 (27), 6809-6811, 2005 | 86 | 2005 |
| Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread—results of a large prospective trial D Andreou, H Boldt, M Werner, C Hamann, D Pink, PU Tunn Annals of oncology 24 (5), 1400-1405, 2013 | 78 | 2013 |
| Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib O Dudeck, M Zeile, P Reichardt, D Pink Annals of oncology 22 (8), 1828-1833, 2011 | 64 | 2011 |
